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ABSTRACT
Background
We have previously reported linkage of markers on chromosome 1q22 to schizophrenia, a
finding supported by several independent studies. Within this linkage region, we have
identified significant linkage disequilibrium between schizophrenia and markers within the
gene for carboxyl-terminal PDZ ligand of neuronal nitric oxide synthase (CAPON). Prior
sequencing of the ten exons of CAPON failed to reveal a coding mutation associated with
illness.
Methods and Findings
We screened a human fetal brain cDNA library and identified a new isoform of CAPON that
consists of the terminal two exons of the gene, and verified the expression of the predicted
corresponding protein in human dorsolateral prefrontal cortex (DLPFC). We examined the
expression levels of both the ten-exon CAPON transcript and this new isoform in postmortem
brain samples from the Stanley Array Collection. Quantitative real-time PCR analysis of RNA
from the DLPFC in 105 individuals (35 with schizophrenia, 35 with bipolar disorder, and 35
psychiatrically normal controls) revealed significantly (p , 0.005) increased expression of the
new isoform in both schizophrenia and bipolar disorder. Furthermore, this increased expression
was significantly associated (p , 0.05) with genotype at three single-nucleotide polymorphisms
previously identified as being in linkage disequilibrium with schizophrenia.
Conclusion
Based on the known interactions between CAPON, neuronal nitric oxide synthase (nNOS),
and proteins associated with the N-methyl-D-aspartate receptor (NMDAR) complex, over-
expression of either CAPON isoform would be expected to disrupt the association between
nNOS and the NMDAR, leading to changes consistent with the NMDAR hypofunctioning
hypothesis of schizophrenia. This study adds support to a role of CAPON in schizophrenia,
produces new evidence implicating this gene in the etiology of bipolar disorder, and suggests a
possible mechanism of action of CAPON in psychiatric illness.
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Schizophrenia (SCZD) is a serious neuropsychiatric illness
estimated to affect approximately 1% of the general
population. Family, twin, and adoption studies have demon-
strated that schizophrenia is predominantly a genetic
disorder, with a high heritability (reviewed in [1]). Multiple
genetic and nongenetic factors are likely to be involved [2]. As
part of a genome-wide search for loci contributing to risk for
schizophrenia, we previously reported linkage, with a
maximum heterogeneity lod score of 6.5, to chromosome
1q21-1q22 (SCZD9) in a group of 22 medium-sized Canadian
families that were selected for study because multiple
relatives were clinically diagnosed with schizophrenia or
schizoaffective disorder [3]. We have also reported the results
of ﬁne linkage mapping of this 1q21-1q22 region in the same
sample of individuals, narrowing the region most likely to
harbor this susceptibility locus to approximately 1 Mb
between APOA2 and D1S2675, again with a maximum
multipoint heterogeneity lod score of 6.5 [4]. Other studies
have also reported linkage [5–8] and linkage disequilibrium
(LD) [9] of schizophrenia to this region. More recently, we
have tested markers from this region for evidence of LD to
schizophrenia, identifying signiﬁcant LD with several markers
within the gene for carboxyl-terminal PDZ ligand of neuronal
nitric oxide synthase (CAPON; also termed nitric oxide
synthase 1 [neuronal] adaptor protein [NOS1AP]) [10].
Association of single-nucleotide polymorphisms (SNPs) with-
in CAPON to schizophrenia has recently been replicated in
the Chinese Han population [11], although with association
detected in the Chinese sample to SNPs located more distal in
the gene than the SNPs associated in the Canadian sample.
CAPON is an attractive candidate for schizophrenia
susceptibility. CAPON was ﬁrst identiﬁed in the rat as a
neuronal nitric oxide synthase (nNOS) binding protein,
capable of disrupting the association of nNOS with the
postsynaptic density scaffolding proteins PSD93 and PSD95
through the binding of the carboxyl terminus of CAPON to
nNOS [12]. The interaction of nNOS with PSD93 and PSD95
is important in targeting nNOS to the postsynaptic N-methyl-
D-aspartate receptor (NMDAR) complex and facilitates the
tight coupling between activation of the NMDAR and nNOS,
allowing nNOS activation by Ca
2þinﬂux through the NMDAR
and producing NMDAR-mediated NO release into the
synaptic structures [13,14]. This places CAPON at the scene
of NMDAR glutamate neurotransmission, long proposed to
be involved in schizophrenia (reviewed in [15]). CAPON can
also serve as an nNOS adaptor protein, with the amino
terminus binding either to a direct target of NO-mediated
activation by S-nitrosylation [16] or to Synapsin [17], resulting
in the localization of nNOS to the presynaptic terminals.
Sequencing of the coding region of CAPON in individuals
fromtheCanadianlinkagesamplefailedtoidentifyanycoding
mutations associated with illness [10], consistent with current
results for other candidate genes for schizophrenia [18].
CAPON has a large, approximately 300-kb genomic extent,
only 1.5 kb of which represents coding sequence. Therefore,
there are many potential sites for regulatory sequences that
could be disrupted and lead to altered gene expression. In this
study, we screened a human cDNA library to identify possible
alternative splice forms of CAPON, documented CAPON
mRNA and protein expression in postmortem tissue from
the dorsolateral prefrontal cortex (DLPFC) of human brains,
andinvestigatedtheexpressionofCAPONbyquantitativereal-
time PCR in the Stanley Array Collection, derived from
DLPFCs of individuals with schizophrenia and with bipolar
disorder, and a set who were psychiatrically normal controls.
Methods
Identification and Characterization of CAPON Transcripts
A human fetal brain arrayed cDNA library (Origene Tech-
nologies, Rockville, Maryland, United States; #LLFB-1001) was
screened using the supplier’s protocol. PCR ampliﬁcation was
performed with primers from CAPON exon 10 (Ex10-F, 59-
AAATCAACAACCTTGCCTAACG-39; Ex10-R, 59-GAAAG-
CACTCCAGCTTCACC-39). Exon 10 sequence was chosen for
screening purposes to identify alternative transcripts that also
contained the nNOS-binding PDZ domain. Individual positive
clones were sequenced on a CEQ 8000 (Beckman Coulter,
Fullerton, California, United States). The transcript for the
previously undescribed shortisoform was further characterized
by 39 and 59 RACE, performed with RACE-ready cDNA from
human brain (Ambion, Austin, Texas, United States). For each
reaction, a pair of nested PCR primers were designed from
short-form 59 UTR sequences (5RACES, 59-TTAGAGGTTC-
CTGGAGGGTGGTGC-39; 5RACESn, 59-TTGAGTCCAAGGA-
GAGGGTAGTGG-39) and 39 UTR sequence (3RACE1, 59-
AATGAATGCAAGCTGATAGCTGAGACTG-39; 3RACE1n, 59-
TGAATCACTGCCACTTGGGTCAGG-39;3 R A C E 2 ,5 9-AGAA-
GGAAGAACCAGGAAAGTGAGATCC-39; 3RACE2n, 59-ATC-
CAGTGTGGCTGAGCCTACCTAGC-39;a n d3 R A C E 3 ,5 9-
ATGTGGATGGAGAGGGCTTGT-39; 3RACE3n, 59-GTGAG-
GAAGGCCGCTTCTAAAT-39) and were used in conjunction
with a set of universal nested primers (supplied). Products were
cloned into TOPO TA cloning vector (Invitrogen, Carlsbad,
California, United States) and sequenced on a CEQ 8000.
The sequence for the novel CAPON transcript has been
deposited in GenBank (http://www.ncbi.nlm.nih.gov/entrez/)
under accession number AY841899.
Human Postmortem Samples
RNA andDNA samples from the StanleyArray Collection of
the Stanley Brain Collection (http://www.stanleyresearch.org/
programs/brain_collection.asp) were analyzed. This is a
collection of biomaterials derived from postmortem brain
specimens from 35 individuals with schizophrenia, 35 individ-
uals with bipolar disorder, and 35 psychiatrically normal
controls. Diagnoses were made by two senior psychiatrists,
applying DSM-IV criteria to medical records, and, when
necessary, telephone interviews with family members. Diag-
noses of unaffected controls were based on structured inter-
viewsbyaseniorpsychiatristwithfamilymember(s)toruleout
DSM-IV Axis I diagnoses of psychiatric clinical syndromes.
Specimens were collected, with informed consent from
next of kin, by participating medical examiners between
January 1995 and June 2002. The specimens were collected,
processed, and stored in a standardized way. Exclusion
criteria for all specimens included: (1) signiﬁcant structural
brain pathology on postmortem examination by a qualiﬁed
neuropathologist, or by premortem imaging; (2) history of
signiﬁcant focal neurological signs premortem; (3) history of
central nervous system disease that could be expected to alter
gene expression in a persistent way; (4) documented IQ under
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determined with an Agilent 2100 Bioanalyzer (Agilent, Palo
Alto, California, United States). Degradation was deﬁned as a
shift in the RNA size distribution toward smaller fragments
and a decrease in ﬂuorescence signal of ribosomal peaks.
Additional exclusion criteria for unaffected controls included
age less than 30 (thus, still in the period of maximum risk) and
substance abuse within 1 y of death or evidence of signiﬁcant
alcohol-related changes in the liver.
DNA and RNA from Brodmann’s area 46 (in the DLPFC)
was available for all individuals in the collection. Genotyping
and expression analyses were conducted with the samples
coded to keep investigators blind to diagnostic status. After
the blind was broken, diagnostic status and a range of clinical
variables were provided for analysis. These included gender,
race, age at time of death, age of onset, postmortem interval
(PMI), brain pH, total brain weight, hemisphere used for RNA
extraction, smoking status at time of death (coded as
nonsmoking for individuals who smoked previously but had
quit), antipsychotic status at time of death, and lifetime
antipsychotic exposure in ﬂuphenazine milligram equiva-
lents. In addition, lifetime alcohol and substance use were
each rated on a scale of 0 to 5 using the categories ‘‘little or
none,’’ ‘‘social,’’ ‘‘moderate past,’’ ‘‘moderate present,’’
‘‘heavy past,’’ and ‘‘heavy present.’’ Total sample storage time
was calculated from date of death to date of experiment, so it
represents the sum of storage time of the brain tissue prior to
RNA extraction and storage time of the extracted RNA.
Overall, the sample was 66% male, with a mean age at death
of 44 y (standard deviation [SD] 8.9 y, range 19–64 y), and was
predominantly Caucasian (97%). The mean PMI was 33 h (SD
16 h, range 9–84 h), and the mean storage time was 5.0 y (SD
1.9 y, range 2.1–9.7 y). Smoking status at time of death was
available for 67 individuals, with 72% of the sample smokers.
Lifetime alcohol use estimates were available on all but one
patient, with 57% of the sample reporting no, little, or social
use, 17% reporting past or present moderate use, and 26%
reporting past or present heavy use. Lifetime substance use
estimates were available on all but two individuals, with 65%
of the sample reporting no, little, or social use, 16% reporting
past or present moderate use, and 19% reporting past or
present heavy use. The mean age of onset for the schizo-
phrenia group was 21.3 y (SD 6.1 y, range 9–34 y) and for the
bipolar group was 25.1 y (SD 9.1 y, range 14–48 y). Further
information about the Stanley Array Collection is available
from the Stanley Medical Research Institute (http://www.
stanleyresearch.org/programs/brain_collection.asp).
Studies of CAPON protein were conducted using brain
specimens from ﬁve normal control individuals (three male
and two female) obtained from the Human Brain and Spinal
Fluid Resource Center (Los Angeles, California, United
States). Individuals ranged in age from 53 to 90 years at time
of death (mean 67.4 y, SD 16.4 y). Samples were recovered and
frozen after a mean PMI of 21.5 h (SD 3.0 h, range 17.8–26.0
h). Specimens were shipped frozen for protein and RNA
extraction in our laboratory. Mean storage time prior to
extraction for these specimens was 3.0 y (SD 1.4 y, range 1.9–
5.3 y); protein and RNA was quantiﬁed within 1 wk of
extraction. To assure a similar composition of each sample
for protein and RNA extractions, samples were ﬁrst ground
while still frozen into a ﬁne powder using liquid nitrogen and
a mortar and pestle. Aliquots of this homogeneous powder
were then used for protein and RNA extraction as below.
Preparation and Western Blotting of Human Brain
Homogenates
Tissue from Brodmann’s area 46 (DLPFC) from the Human
Brain and Spinal Fluid Resource Center samples was homo-
genizedwith10timesthe equivalentvolume perweight of TEE
(25mMTris-HCl[pH7.4],1mMEDTA,1mMEGTA,and1mM
PMSF) using a serrated Teﬂon pestle. Ten micrograms of
protein were loaded and resolved on a 12% SDS polyacryla-
mide gel and transferred to polyvinylidene diﬂuoride mem-
brane (Immobilon P; Millipore, Billerica, Massachusetts,
United States) in transfer buffer lacking SDS, which was
determined to interfere with detection of the short isoform of
CAPON (CAPON-S). Blots were probed with a rabbit antibody
to CAPON (Santa Cruz Biotechnology, Santa Cruz, California,
United States; #R-300) and visualized using ECL plus (Amer-
sham Biosciences, Piscataway, New Jersey, United States) with
a secondary antibody coupled to horseradish peroxidase. For
actin normalization, blots were incubated in strip buffer (62.5
mM Tris-HCl [pH 7.4], 2% SDS, and 90 lM b-mercaptoetha-
nol) at 65 8C for 20 min with agitation, followed by probing
with a rabbit antibody to actin (the antigen corresponds to
amino acids 20–33, conserved in all actin isoforms; Sigma,
Saint Louis, Missouri, United States) using the procedure
described above. To ensure that quantiﬁcation used an
exposure that was within the linear range of the ﬁlm used to
image the blot, a series of images with increasing exposure
time to the blot were developed. The intensity of the bands on
each image was quantiﬁed using Image Pro image analysis
software (Media Cybernetics, Silver Spring, Maryland, United
States) and plotted to determined at what exposure time the
darkest band intensities were no longer in the linear range.
Nonsaturatedexposureswerethenusedtodeterminetheratio
of CAPON to actin. Using ImagePro image analysis software,
the relative immunoreactivities of anti-CAPON bands were
calculated as (a   b)/(c   d), where a ¼ sum of pixels in each
CAPON immunoreactive band; b ¼ sum of pixels in an area
equivalent to that occupied by a within a nonreactive portion
of the lane; c ¼ sum of pixels in each actin immunoreactive
band; and d ¼ sum of pixels in an area equivalent to that
occupied by c within a nonreactive portion of the lane.
COS-7 Cell Culture and Transfection
COS-7 cells were plated at 70%–80% conﬂuence and
maintained in Dulbecco’s Modiﬁed Eagle Medium (Invitro-
gen), supplemented with 7.5% fetal bovine serum and 7.5%
horse serum in a 7% CO2 atmosphere. Cells were transfected
with 0.5 lg of plasmid from the Origene library containing the
CAPON short-form RNA, cloned behind the CMV promoter in
pCMV6-XL4, using the LipofectAMINE 2000 method (Invi-
trogen) following the manufacturer’s instructions. After
allowing 48 h for expression, cells were lysed in TEE, and
lysates were analyzed by Western blotting as described above.
RNA Extraction
Total RNA was extracted from the Human Brain and
Spinal Fluid Resource Center samples using RNeasy Lipid
Tissue Mini Kits (Qiagen, Valencia, California, United States),
following the manufacturer’s instructions. RNA was quanti-
ﬁed with a Pharmgena UV spectrometer. Quality of the
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100 V for 40 min, staining with ethidium bromide, and
visualization under UV light.
RNA Quantification
Total RNA (5 lg) was treated with the DNA-free Kit
(Ambion) in accordance with the manufacturer’s protocol to
eliminate DNA contamination. The resulting DNase-treated
RNA was used in a 40-ll reverse transcriptase reaction to
synthesize cDNA following the SuperScript II First-Strand
cDNA Synthesis protocol (Invitrogen), including optional
RNaseOUT treatment. Samples were then quantiﬁed using
real-time PCR. The previously described primer pair
NN05224/NN05225 (Human Unidentiﬁed Gene-Encoded da-
tabase [http://www.kazusa.or.jp/huge/index.html] clone
KIAA0464) was used for quantiﬁcation of full-length CAPON
[19,20].This primerpairproducesa 338-bpproduct thatspans
the boundary of exons 7 and 8. The primers speciﬁc for the
short form were designed using Primer Express Software
Version 2.0 (Applied Biosystems, Foster City, California,
United States). The forward primer (Short-F: 59-CATT-
CATGTCCCTCTCTTCTCTC-39) is located in the 59 coding
sequence that is unique to the short form transcript, the
reverseprimer (Short-R,59-AATGCAGGTCCTCTGGCTTAG-
39) is located within exon 10, and the pair produces a 321-bp
product that spans the boundary of exons 9 and 10. The
housekeeping gene ACTB, the gene encoding beta-actin, was
used as reference gene to normalize the total RNA input. The
forward (b-actin-F, 59-CATCCTCACCCTGAAGTACCC-39)
and reverse (b-actin-R, 59-GAGAAGATGACCCAGAT-
CATGTTT-39) primers produce a 184-bp product that spans
the boundary of exons 3 and 4. Real-time PCR analysis was
conducted using 1 ll of a 1:5 dilution of cDNA, 0.1 lM of each
primer, and 5 ll of SYBR Green Master Mix (Applied
Biosystems) in a total reaction volume of 10 ll in a 384-well
plate on an ABI Prism 7900HT sequence detector system
(Applied Biosystems). Samples were initially warmed to 50 8C
for 2 min, then the AmpliTaq Gold DNA polymerase was
activatedbyheatingto958Cfor10min.PCRampliﬁcationwas
performedwith40–50 cycles of958Cfor30s,588C(full-length
experiments) or 61 8C (short-form experiments) for 40 s, and
72 8C for 1 min. Each real-time PCR assay was repeated three
times. The standard curve used for determining the relative
quantityofeachisoformineachsamplewasconstructedbythe
ampliﬁcation of serial dilutions of pooled brain cDNA. Ineach
experiment, the R
2 value of the standard curve was greater
than 0.98, and the no-template control produced no detect-
able signal. Dissociation curve analysis was conducted on all
PCR products to ensure that only a single product was present
in the reaction. Real-time PCR data acquisition and analysis
were performed using SDS v2.0 software (Applied Biosystems).
SNP Genotyping
DNA samples from the Stanley Array Collection were
genotyped for three SNPs from dbSNP, rs1415263, rs4145621,
and rs2661818, that were previously identiﬁed as being in
linkage disequilibrium with schizophrenia by a primer exten-
sion strategy (Pyrosequencing, Uppsala, Sweden) using the
automated PSQ HS96A platform as previously described [10].
Statistical Analyses
RNA amounts were quantiﬁed by the ABI Relative
Quantitation of Gene Expression protocol (Applied Biosys-
tems; http://docs.appliedbiosystems.com/pebiodocs/04303859.
pdf). The results from three repeat assays were averaged to
produce a single mean quantity value for each mRNA for each
individual. The quantity values of the target gene were then
normalized over the quantity values of the reference gene
ACTB (encoding beta-actin) to produce normalized expres-
sion quantities. These are unitless measures of the relative
amount of transcript that is present in each individual.
Normalizedexpressionquantitiesandpatientvariableswere
analyzed with SAS v8.2 for UNIX software (SAS Institute, Cary,
North Carolina, United States) and with the R statistical
environment [21]. Correlation between protein and mRNA
levels in control brain samples from the Human Brain and
Spinal Fluid Resource Center was tested with Pearson’s
productmomentcorrelation.ForthesamplesfromtheStanley
Array Collection, potentially confounding variables (Table 1)
were tested for association with CAPON expression in all
individuals.AsCAPONexpressionlevelscorrelatedwithtimeof
storage, subsequent analyses included storage time as a
covariate. Effect of exposure to antipsychotics (either as a
dichotomous trait or a quantitative estimate of total lifetime
exposure) was examined only in patients with bipolar disorder
or schizophrenia. Continuous variables (age at death, post-
mortem interval, brain pH, and brain weight) were tested by
regression; dichotomous variables (gender, brain hemisphere
analyzed, smoking status at time of death, and history of
exposure to antipsychotic medication) and ordinal variables
(lifetime alcohol use and lifetime substance abuse) were tested
by ANOVA. The strength of the association with CAPON
expression was measured with Pearson’s product moment
correlation for continuous variables (except for quantitative
lifetime antipsychotic exposure, for which Spearman’s corre-
lation was used) and Kendall’s rank correlation for binary and
ordinal variables. The relationship between gene expression
levels and diagnostic group was summarized with Kendall’s
rankcorrelationandtestedwithANOVA,andtherelationship
between gene expression levels and age of onset within the
bipolar and schizophrenia groups was summarized with
Pearson’s product moment correlation and tested with
regression. The relationship between genotype and CAPON
expressionwas analyzedusingANOVAwitha termforyearsof
Table 1. Correlations between CAPON Isoform Expression and
Possible Confounding Variables
Variable Full Length Short Form
Correlation p-Value
a Correlation p-Value
a
Age
b  0.05 0.63  0.03 0.75
PMI
b 0.08 0.44 0.09 0.38
Brain pH
b 0.16 0.11 0.07 0.49
Brain weight
b 0.03 0.74 0.04 0.68
Storage time
b 0.50 ,0.0001  0.33 0.0006
Gender
c  0.03 0.98 0.11 0.39
Hemisphere
c  0.003 0.62 0.02 0.81
Smoking status at time
of death
c 0.04 0.96  0.04 0.60
Lifetime alcohol use
c  0.01 0.34 0.06 0.50
Lifetime substance abuse
c 0.07 0.89 0.12 0.21
ap-Values from ANOVA.
bPearson’s product moment correlation shown for continuous variables.
cKendall’s rank correlation tau shown for ordinal variables.
DOI: 10.1371/journal.pmed.0020263.t001
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effect of the SNP, and a term for a recessive effect of the SNP.
Results
Identification and Characterization of Two Human CAPON
Isoforms
Screening of a human fetal brain cDNA library resulted in
the isolation of four distinct clones. Three clones (‘‘CAPON
full-length’’) contained inserts of approximately 2.5 kb,
corresponding to exons 1–10, as previously described in the
NCBI reference sequence for CAPON [12,22], except that exon
4 from these clones was missing the ﬁrst 15 bp listed in the
reference sequence. The fourth clone (‘‘CAPON short-form’’)
contained an insert of 4 kb with a unique 59 untranslated
region (UTR) corresponding to genomic sequence from
intron 8, followed by exons 9 and 10, and a 39 UTR longer
than that contained by the other clones or in the reference
sequence. This transcript is predicted to produce a 211 amino
acid protein, including 18 novel amino acids at the amino
terminus, and will contain the CAPON PDZ-binding domain.
The previously undescribed short-form transcript of
CAPON was further characterized by 59 and 39 RACE. The 59
UTR was 2,367 bp, while the longest 39 RACE product ended
2,556 bp downstream of the stop codon. From these results,
the total length of the short-form mRNA was calculated to be
5,559 bp. Due to the much longer 59 and 39 UTRs, the CAPON
transcript encoding the short-form of the protein is actually
signiﬁcantly longer than the transcript that encodes the full-
length protein. The gene, transcripts, and predicted protein
structures of the two forms are shown in Figure 1.
Protein and total RNA were extracted from Brodmann’s
area 46 (DLPFC) of postmortem samples from ﬁve normal
controls, COS-7 cell that had been transfected with cDNA
encoding the CAPON short-form, and untransfected COS-7
cells that normally express the CAPON long form. Western
blots of these samples were probed with a rabbit polyclonal
antibody raised against the carboxyl terminus of CAPON.
This antibody is predicted to interact with both the full-
length and short-form of CAPON, since the antigen used to
generate the antibody is in the carboxyl termini of both
forms. Bands were observed at the expected sizes, near the 75-
kDa marker for the full-length protein and near the 30-kDa
marker for the short-form (Figure 2). There appears to be two
smaller forms of the full-length CAPON (CAPON-L bracket,
Figure 2), which could be due to posttranslational modiﬁca-
tion (i.e., phosphorylation) of CAPON. For example, analysis
by software designed to identify potential sites for phosphor-
ylation by protein kinase C (http://mpr.nci.nih.gov/mpr/
ScanProteinForPKCSitesPage.aspx) identiﬁed ﬁve such sites
in the full-length CAPON sequence. The short form of
CAPON appears as a doublet, although the presence of the
lower band (CAPON-S9) in untransfected COS-7 cells may
indicate that this band is caused by recognition by the
CAPON antibody of a cross-reacting protein. The appearance
of the higher band (CAPON-S) in the transfected cells, which
clearly comigrates with a band in human brain tissue,
indicates that the short-form transcript is translated into a
protein of the expected size in DLPFC.
As protein samples were not available for the Stanley Array
Collection samples, we tested the correlation between protein
and RNA expression using the normal control brain samples
to determine if RNA levels could be used as a reasonable
indicator of protein expression for CAPON. CAPON protein
levels were quantiﬁed from Western blot image analysis and
were normalized to levels of actin protein, while RNA levels
were quantiﬁed by reverse-transcription real-time PCR
normalized to levels of ACTB (beta-actin). For full-length
CAPON, the correlation between protein and RNA levels was
Figure 1. CAPON Gene Structure, Isoforms, and Protein Functional
Domains
CAPON full-length transcript and protein illustrations are based on NCBI
reference sequences.
(A) Genomic organization of CAPON. Exons are represented by numbered
boxes; 59 and 39 UTR are represented by half-height boxes.
(B) CAPON transcripts. 59 and 39 UTR are represented by yellow shaded
boxes, exons by white boxes.
(C) CAPON proteins. The phosphotyrosine-binding domain (PTB) is
shaded green, and the PDZ-binding domain is shaded blue.
DOI: 10.1371/journal.pmed.0020263.g001
Figure 2. Western Blot of CAPON Protein Isoforms in DLPFC from Normal
Control Individuals
Tissue from Brodmann’s area 46 (DLPFC) from five individuals was
homogenized in TEE. Proteins were resolved by SDS-PAGE and
transferred to PVDF membrane. Blots were probed with rabbit polyclonal
antibodies to CAPON and actin, and proteins were detected using
chemiluminescence. Band intensities for CAPON-L, CAPON-S, and
CAPON-S þ CAPON-S9 were calculated and normalized to the intensities
of the corresponding actin bands. Untransfected COS-7 cells expressing
CAPON-L and CAPON-S9 (COS-7/NT) and COS-7 cells expressing
recombinant CAPON-S (COS-7/CAPON-S) and were used as controls for
these proteins. CAPON-L appears to include multiple bands, possibly due
to phosphorylation.
DOI: 10.1371/journal.pmed.0020263.g002
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correlation was also signiﬁcant (p ¼ 0.0049) with r ¼ 0.97
between the RNA and protein levels of the S band, which
corresponds to the size of the cloned CAPON product. While
it seems likely that the S9 band represents a cross-reacting
protein, given its presence in untransfected COS-7 cells, it is
possible that it could represent a modiﬁed form of the short-
form protein. Considering the CAPON short-form product as
the sum of the S and S9 bands, the correlation with RNA levels
remained signiﬁcant (p ¼ 0.030), with r ¼ 0.91.
Analysis of CAPON Isoform Expression by Diagnosis
Expression levels of both CAPON isoforms were determined
by reverse-transcription real-time PCR for all 105 samples
from the Stanley Array Collection. Expression levels were
normalizedtoACTB(beta-actin),andthesenormalizedrelative
expression levels were used for all subsequent analyses. No
signiﬁcantcorrelationsweredetectedbetween mRNAlevelsof
either CAPON isoform and the potentially confounding
variables of age at death, PMI, brain pH, brain weight, gender,
hemisphere, smoking status at time of death, lifetime alcohol
use, or lifetime substance abuse (Table 1). CAPON expression
levelswerefound tobe signiﬁcantly(p ,0.001)correlated with
lengthofsamplestorageforbothisoforms(Table1).Therefore,
for all subsequent analyses storage time was used as covariate.
The potential confounding effects of antipsychotic medi-
cation treatment on CAPON expression levels were also very
important to examine, but since all of the patients with
schizophrenia and none of the controls had been treated with
such medications, the effects of treatment and diagnosis
could not be separated by analyses that included these
groups. Within the 35 individuals in the bipolar group,
however, 18 individuals were on antipsychotic medication at
t h et i m eo fd e a t h ,1 1i n d i v iduals had never received
antipsychotic medication, and six individuals were not on
antipsychotic medication at time of death, but had been
treated with these medications at some point in the past.
CAPON levels were compared between antipsychotic-treated
and untreated individuals with bipolar disorder. Neither a
positive history of lifetime antipsychotic use nor antipsy-
chotic use at time of death was signiﬁcantly correlated with
CAPON short-form expression within the bipolar group
(Table 2). In contrast, expression of full-length CAPON was
signiﬁcantly correlated with treatment (Table 2), with a 40%
decrease in mean expression in the patients (n ¼ 24) with
bipolar disorder and a history of treatment with antipsy-
chotics in the past or at time of death (p ¼ 0.003), and a 45%
decrease in patients (n ¼ 18) receiving antipsychotics at time
of death (p ¼ 0.0007), when compared to antipsychotic-
untreated individuals (n ¼ 11) with bipolar disorder. An
estimate of total lifetime antipsychotic medication was
available for all but one individual in the bipolar and
schizophrenia groups with a positive history of antipsychotic
treatment (n ¼ 58). No signiﬁcant correlations were found
between levels of lifetime antipsychotic exposure and
expression of either CAPON isoform (Table 2).
Overall, there was no signiﬁcant difference in CAPON full-
length mRNA expression across diagnostic categories
(Figure 3). Since treatment with antipsychotics may inﬂuence
expression of the full-length isoform, we examined expres-
sion of this transcript in antipsychotic-naı ¨ve patients with
bipolar disorder. While mean CAPON full-length mRNA levels
were increased by 24% in patients with bipolar disorder but
no history of exposure to antipsychotic medication (n¼11) as
compared to normal controls, this increase did not reach
statistical signiﬁcance (p ¼ 0.11). Results were similar when
comparing bipolar patients not receiving antipsychotic
medication at time of death, regardless of past treatment
history, (n ¼ 17) to normal controls, with a 18% increase in
full-length CAPON levels (p ¼ 0.14).
Mean CAPON short-form mRNA levels were signiﬁcantly
increased by 48% in the schizophrenia group (p¼0.0035) and
50% in the bipolar group (p ¼ 0.0002) as compared to the
control group (Figure 4). The schizophrenia and bipolar
groups did not differ signiﬁcantly from each other in CAPON
short-form expression (p ¼ 0.94). CAPON short-form expres-
sion was signiﬁcantly correlated with the age of onset in the
schizophrenia group (Pearson’s r¼0.53, p¼0.0008), but not in
the bipolar group (r¼ 0.02, p¼0.92). This signiﬁcance (or lack
thereof) is unchanged when age of death is included as a
covariate. The majority of samples were from individuals of
European decent (97%), with one African American individ-
ual with bipolar disorder, one Native American individual
with bipolar disorder, and one Hispanic individual with
schizophrenia. None of these individuals exhibited extreme
values for expression of either CAPON isoform, and re-analysis
with these patients excluded did not change which compar-
isons reached statistical signiﬁcance (unpublished data).
Analysis of CAPON Isoform Expression by Genotype
All individuals were genotyped at rs1415263, rs4145621,
and rs2661818, three SNPs within CAPON that were previously
Table 2. Effect of Antipsychotic Treatment on CAPON Isoform Expression
Variable Group
a Full Length Short Form
Correlation
b p-Value
c Correlation
b p-Value
c
Any history of antipsychotic use
d BP  0.38 0.0028  0.05 0.51
Antipsychotic use at time of death
d BP  0.52 0.0002  0.14 0.29
Lifetime antipsychotic exposure
e BP  0.19 0.26  0.05 0.79
Lifetime antipsychotic exposure
e SCZ 0.05 0.57  0.09 0.78
Lifetime antipsychotic exposure
e BPþSCZ 0.13 0.59  0.14 0.74
aBP, bipolar; SCZ, schizophrenia.
bExpression values for correlations controlled for length of storage.
cp-Values from ANOVA using storage time as a covariate.
dCorrelation estimated with Kendall’s rank correlation.
eLifetime dose in fluphenazine milligram equivalents for patients with a positive history of neuroleptic exposure. Correlation estimated with Spearman’s correlation; log of exposure used for ANOVA.
DOI: 10.1371/journal.pmed.0020263.t002
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schizophrenia [10]. For each SNP, individuals with one or two
copies of the previously identiﬁed associated allele were
observed to have higher group mean CAPON short-form
expression than the group of individuals homozygous for the
unassociated allele (Figure 5). All three SNPs individually
showed signiﬁcant differences among means for the short-
form expression (rs1415263, p ¼ 0.019; rs4145621, p ¼ 0.022;
rs2661818, p ¼ 0.019), while none showed signiﬁcantly differ-
ent means for the full-length expression (rs1415263, p ¼0.67;
rs4145621, p ¼ 0.52; rs2661818, p ¼ 0.50). Genotypes with one
or two copies of the associated alleles had higher mean short-
form expression (rs1415263, 30%; rs4145621, 32%; rs2661818,
34%). None of the SNPs showed signiﬁcant expression
differences between individuals heterozygous or homozygous
for the associated allele. Given that the prior demonstrated
correlation between CAPON full-length expression and anti-
psychotic treatment could represent a medication treatment
effect, the correlation analysis between CAPON full-length
expression and genotype was rerun using only individuals not
receiving antipsychotic medications at time of death (35
controls and 17 individuals with bipolar disorder). Again,
there were no signiﬁcant differences in mean CAPON full-
length expression among genotypes for any of these SNPs
(rs1415263, p¼0.41; rs4145621, p¼0.82; rs2661818, p¼0.58).
Discussion
Our screening of a human fetal total brain cDNA library
resulted in the identiﬁcation of two isoforms of CAPON
mRNA corresponding to two forms of CAPON protein. Our
screen used only primers from exon 10, so we would not have
detected isoforms lacking this portion of the gene. One of the
two identiﬁed transcripts encompasses ten exons and
encodes a 501 amino acid protein containing two known
functional domains, an amino-terminal phosphotyrosine-
binding domain and a carboxyl-terminal PDZ-binding do-
main. This full-length form corresponds to transcripts
previously identiﬁed in the rat and human [12,22]. The
second transcript contains the last two exons of CAPON and is
predicted to produce a short form of the protein, 211 amino
acids long and containing the PDZ-binding domain. Prior
work has demonstrated that the terminal 125 amino acids of
the full-length protein are sufﬁcient to bind the PDZ-domain
of nNOS and interfere with the binding between nNOS and
PSD93 or PSD95 [12]. In addition to the ability of CAPON to
bind to nNOS, the terminal 125 amino acids also appear to be
able to directly bind to the second PDZ domain of PSD95 [23],
the normal site of nNOS binding to PSD95 [13]. As the ﬁrst
180 amino acids of CAPON have been previously demon-
Figure 4. ACTB (Beta-Actin)–Normalized CAPON mRNA Short-Form
Expression by Diagnosis
Expression levels are least squares means. Mean values per category are
plotted with 95% confidence intervals. The number of individuals per
sample is indicated within each bar. Expression is significantly higher in
patients with schizophrenia (p ¼ 0.0013) and bipolar (p ¼ 0.0009) as
compared to controls. The mean (95% confidence interval lower bound,
upper bound) for the control, schizophrenia, and bipolar groups are 1.34
(1.05, 1.62), 2.02 (1.73, 2.30), and 2.05 (1.77, 2.34), respectively.
DOI: 10.1371/journal.pmed.0020263.g004
Figure 5. ACTB (Beta-Actin)–Normalized CAPON mRNA Short-Form
Expression by Genotype
Expression levels are least squares means. Individuals from all three
diagnostic classifications are included, grouped only by genotype. Mean
values per genotype for each SNP are plotted with 95% confidence
intervals. The number of individuals per genotype is indicated within
each bar. SNP alleles are given for forward strand sequence. All three
SNPs exhibit significantly (p , 0.05) different levels of CAPON expression
by genotype, with a dominant effect. Higher levels of CAPON are seen in
individuals with one or two copies of alleles previously identified as
associated with schizophrenia (T, rs1415263; C, rs4145621; and C,
rs2661818). The mean (95% confidence interval lower bound, upper
bound) for the three genotypes for each SNP are as follows. For
rs1415263: 1.54 (1.29, 1.80) for CC; 2.07 (1.81, 2.34) for CT; and 1.83 (1.36,
2.29) for TT. For rs4145621: 1.51 (1.25, 1.78) for TT; 2.01 (1.74, 2.27) for TC;
and 2.01 (1.61, 2.41) for CC. For rs2661818: 1.49 (1.21, 1.76) for GG; 1.96
(1.70, 2.23) for CG; and 2.04 (1.68, 2.41) for CC.
DOI: 10.1371/journal.pmed.0020263.g005
Figure 3. ACTB (Beta-Actin)–-Normalized CAPON mRNA Full-Length
Expression by Diagnosis
Expression levels are least squares means. Mean values per category are
plotted with 95% confidence intervals. The number of individuals per
sample is indicated within each bar. Level of expression does not differ
significantly by diagnostic group. The mean (95% confidence interval
lower bound, upper bound) for the control, schizophrenia, and bipolar
groups are 1.28 (1.12, 1.45), 1.33 (1.17, 1.49), and 1.16 (0.99, 1.32),
respectively.
DOI: 10.1371/journal.pmed.0020263.g003
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terminal targets Dexras1 and Synapsin [16,17], it would seem
that only the full-length form of CAPON would be able to
serve as an adaptor protein between nNOS and these targets.
A physiological role of the short form would likely be limited
to the competitive inhibition of binding of other ligands to
the PDZ domains of nNOS and PSD93 or PSD95.
There are signiﬁcant obstacles to the study of gene
expression in the human brain. Obtaining high-quality
postmortem samples suitable for RNA extraction is difﬁcult
and labor-intensive. Obtaining appropriate matched control
groups is also a challenge. While it may be possible to collect
samples with relative consistency across some variables, such
as PMI or brain pH, many factors that may potentially affect
gene expression, such as treatment history and substance use,
are beyond the control of investigators. The rate of collection
of individuals with too many clinical restrictions (e.g., treat-
ment-naı ¨ve individuals with schizophrenia and no history of
substance abuse, alcohol use, or smoking) would be too slow
to produce a useful number of samples. Added to these
clinical variables is likely etiological heterogeneity, with only a
subset of affected individuals expected to harbor a primary
causative mutation in any given gene. All of these factors may
lessen the chance that signiﬁcant differences in gene
expression can be demonstrated using a particular sample.
We chose to conduct our expression studies using the
Stanley Array Collection, as this collection contains samples
from more individuals than other postmortem collections,
and the samples were collected in a standardized fashion with
an emphasis on obtaining high-quality RNA for expression
studies. Limitations of this collection include the facts that
protein samples were not available for parallel analysis, and
that only one brain region, the DLPFC, was available for
study. However, this brain region has long been hypothesized
to be involved in schizophrenia, implicated by evidence from
neuropsychological, neuroimaging, histopathological, and
neurochemical studies (reviewed in [24]).
Ourresultssuggest that mRNA expression of theshort-form
of CAPON is signiﬁcantly (p , 0.005) increased in patients with
either schizophrenia or bipolar disorder. If the short-form
protein behaves as predicted, it would disrupt the binding of
nNOS to PSD95 through competitive inhibition and remove
nNOS from the NMDAR complex, thereby decoupling NO
generation from NMDAR activation. This could produce a
picture consistent with the NMDAR hypofunction hypothesis
of schizophrenia. Based on our data, expression of short-form
mRNA does not appear sensitive to treatment with anti-
psychotic medication. Full-length CAPON mRNA expression,
in contrast, appears to be highly inﬂuenced by treatment with
antipsychotic medication, at least in bipolar disorder. It will
be of interest to further investigate and conﬁrm this effect in
subsequent studies. Pre- and postexposure expression studies
in animals may be helpful in determining if the relationship
between antipsychotic treatment and decreased CAPON
mRNA expression is causal. While we found no signiﬁcant
group differences in expression levels between patients with
schizophrenia or bipolar disorder and normal controls, it is
possible that this is due to the normalization of full-length
CAPON mRNA expression by antipsychotic treatment. Addi-
tional expression studies in individuals with schizophrenia not
receiving antipsychotic medication would be of great interest
to assess this possibility.
The Stanley Array Collection consists of samples collected
from several locations within the United States, and therefore
represents a sample that is independent from our Canadian
familial schizophrenia collection. Nonetheless, there is
signiﬁcant evidence for association between affection phe-
notypes and the same alleles at three different SNPs in both
samples. Consistent with the hypothesis that CAPON short
form overexpression is associated with schizophrenia, the
alleles observed associated with schizophrenia in our Cana-
dian sample are signiﬁcantly (p , 0.05) associated with higher
short form expression in the Stanley Array Collection.
The three SNPs investigated span nearly 98 kb and are
located in introns 2 and 3 of CAPON, the most proximal being
70 kb upstream from the short-form transcription start site.
Although there is evidence for LD spanning large regions
within CAPON, it is unlikely that these SNPs are in tight
disequilibrium with polymorphisms in the short-form basal
promoter [10,25]. Our prior work on this gene revealed that
the three SNPs used in this study are in signiﬁcant (p , 0.0001)
linkage disequilibrium with each other (rs1415263 and
rs4145621, D9 ¼ 0.748; rs1415263 and rs2661818, D9 ¼ 0.801;
rs4145621 and rs2661818, D9 ¼ 0.491), while being in much
weaker LD (D9 values ranging from 0.074 to 0.432) with SNPs
located in intron 8 (rs7521206) and exon 9 (rs348624) [10].
Moreprobable isthat theSNPsusedinthepresent study arein
LD with a mutation in an enhancer region that is located at
some distance upstream of the short-form transcript. En-
hancers can regulate geneexpression from distances of up to1
Mb [26], and mutations in enhancer sequences have been
shown to be responsible for a number of human diseases [27].
Additional studies are needed to further examine the level
of CAPON protein among individuals with different psychi-
atric diagnoses, in both the DLPFC and other regions of the
brain. The implication that CAPON may inﬂuence schizo-
phrenia susceptibility through disruption of NMDAR func-
tioning adds to the list of candidate genes that may act at this
receptor system, including Neuregulin 1 [28], D-amino acid
oxidase and G72 [29], Dysbindin [30], and PPP3CC [31].
Additional work on the interaction of these different
candidates may also further our understanding of the genetic
component of schizophrenia susceptibility.
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Patient Summary
Background Although the exact cause of schizophrenia remains
unknown, people who inherit certain variations in genes are thought
to be at higher risk. Scientists have been trying to get a handle on which
genes are involved. They hope that this will help them understand the
disease better and eventually lead to treatments and maybe even
prevention. So far, a number of genes have been implicated, but it is
important to confirm such findings, and to find out what the genes
actually do that could lead to abnormalities in the brain.
Why Was This Study Done? The scientists who did this study had
previously discovered that a gene called CAPON might be involved in
schizophrenia. The scientists had found that certain variations in the
region of the gene were more common in patients with schizophrenia. In
this study, the researchers examined CAPON in more detail and asked
two main questions: (1) Are there differences in the activity of the CAPON
gene in brains from patients with schizophrenia and bipolar disorder
compared with those from healthy individuals? (2) Could they confirm
the link between variations in the CAPON gene and the disease in a
second study of different patients with schizophrenia?
What Did the Researchers Do and Find? They looked for variations in
the CAPON gene and measured the level of CAPON gene expression in
samples from a collection of postmortem brain specimens. The collection
contained brain tissue samples from 35 patients with schizophrenia, 35
patients with bipolar disorder, and 35 patients without psychiatric illness
(known as ‘‘controls’’). Genes are templates for proteins (which make up
the majority of active components in cells and body), and the researchers
foundthattheCAPONgeneisatemplatefortwodifferentproteins,ashort
formandalongform.Brainsamplesfrompatientswithschizophrenia and
bipolar disorder had higher levels of the short form than brain samples
from patients without psychiatric illness. Moreover, these higher levels of
the short version were predominantly seen in people with versions of
the CAPON gene that had been previously linked to schizophrenia.
What Does This Mean? These results lend more support to the idea that
CAPON is somehow involved in schizophrenia. Given that studies by
other groups also point to a link between CAPON and schizophrenia, it
seems clear that further study of CAPON is justified. The findings here
suggest that we need to learn more about the short version of CAPON,
and specifically what exactly the CAPON protein does in the brain.
Because of the limitations of working with human postmortem samples,
it is likely that most of the next round of experiments will be done in cell
culture and in animal models.
Where Can I Find More Information Online? The following Web sites
provide information on schizophrenia.
US National Institutes of Mental Health (search for ‘‘schizophrenia’’):
http://www.nimh.nih.gov/
UK National Institute for Health and Clinical Excellence pages on
schizophrenia:
http://www.nice.org.uk/page.aspx?o¼42770
The National Alliance for Research on Schizophrenia and Depression
(NARSAD):
http://www.narsad.org/
The National Alliance for the Mentally Ill (NAMI):
http://www.nami.org/
The Schizophrenia Society of Canada:
http://www.schizophrenia.ca/
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